Access to POEMs and Essential Evidence Plus will no longer be included in CMA membership as of Dec. 1, 2023.
Clinical Question
Does mirtazapine reduce agitated behaviors in persons with dementia?
Bottom line
Mirtazapine did not reduce agitated behaviors among persons with dementia nor reduce caregiver burden. There were more deaths in the treated group, which (even though the number was not statistically significant) warrants caution with the use of this medication in persons with dementia. 1b
Reference
Study design: Randomized controlled trial (double-blinded)
Funding: Government
Setting: Outpatient (any)
Synopsis
This was a well-designed randomized controlled trial of mirtazapine versus placebo (N = 204) for the treatment of agitation among people with dementia. It was conducted in 26 UK National Health Service clinical centers over 12 weeks. Participants were enrolled if they met the criteria from the National Institute of Neurological and Communicative Diseases and Stroke – Alzheimer’s Disease and Related Disorders Association for probable or possible Alzheimer’s disease and had coexisting agitation defined as a Cohen-Mansfield Agitation Inventory (CMAI) score of at least 45. The investigators also required that the agitated behaviors had not responded to nonpharmacological management. Potential participants were excluded if they were considered too unwell (eg, suicide risk), had medical contraindications, or did not have a family or professional caregiver to provide information. The target dose was 45 mg daily of mirtazapine, three 15-mg capsules in one daily dose or identical-appearing placebo. The authors started with one capsule daily and increased by one capsule daily in weeks 2 and 3, as tolerated. They allowed additional titration as needed. Analysis was by intention to treat. Adequate clinical response was considered to be improvement by at least 6 points on the CMAI at the 12-week follow-up. The mean dose in the treated group was 30.5 mg. The severity of agitation improved in both groups over time and at no point reached a statistically significant difference. Caregiver burden was not lower in the treated group at any point, including no difference in anxiety. There were several more deaths in the treated group (7 vs 1), but the study was not powered to assess this outcome.
Reviewer
Linda Speer, MD
Professor and Chair, Department of Family Medicine
University of Toledo
Toledo, OH
Comments
Test
Test
Treatment of behaviours in dementia
Any evidence for treating behaviours and mood in dementia is welcome. Often the choices besides doing nothing is pick your poison. The target dose was 45 mg daily of mirtazapine, three 15-mg capsules in one daily dose or identical-appearing placebo. The authors started with one capsule daily and increased by one capsule daily in weeks 2 and 3, as tolerated. Lower doses of mirtazapine may have a desired soporific effect, with benefits for mood and behaviour, without the possible effect on mortality. Mirtazapine can have a benefit is dose as low as 3.75 mg.
Another perspective
Time to further study what damage mirtazapine does in non demented populations?
bad habit
bad habit
mirtazapine in elderly pts
increased side effects and not effective in treating dementia symptoms